Revestive · Gattex · GLP-2 analog
FDA-approved GLP-2 analog — intestinal growth and short bowel syndrome.
FDA
Approved
WADA
Not Listed
HALF-LIFE
~2 hours
ROUTE
SubQ injection
SCHEDULE
Daily
In Plain English
FDA-approved GLP-2 analog — intestinal growth and short bowel syndrome.
Status & Legality
NATTY?
No Test ExistsNo established test exists for this compound.
FDA
ApprovedFDA approved for human use.
WADA
Not ListedNot currently on WADA prohibited list.
COMPOUNDING
Rx AvailableAvailable at licensed pharmacies with prescription.
PRESCRIBED
By prescriptionPhysicians can prescribe this compound legally.
ROUTE
SubQ injectionAdministration via subq injection.
Short bowel syndrome
Intestinal mucosal growth
Crohn's disease
Gut repair
Teduglutide (Gattex/Revestive) is an FDA-approved GLP-2 analog that promotes intestinal villus growth and crypt cell proliferation. It significantly reduces parenteral nutrition requirements in short bowel syndrome patients. Research explores its utility in Crohn's disease remission and post-surgical gut rehabilitation.
Abdominal pain
Nausea
Injection site reactions
Fluid retention
Potential colorectal polyp growth (requires colonoscopy monitoring)
Skipping the mandatory colonoscopy monitoring — Teduglutide promotes intestinal cell proliferation which requires surveillance for polyp development; not optional
Not dose-adjusting by body weight — Teduglutide is one of the few peptides with strict weight-based dosing protocols
Using compounded versions without quality verification — for a compound this potent and specific, pharmaceutical-grade or verified compounded preparations are critical
Oral medications — Teduglutide enhances intestinal absorption, which can increase blood levels of concurrently taken drugs; monitor narrow therapeutic index drugs
Anticoagulants (warfarin) — enhanced intestinal absorption may increase INR; monitor more frequently
Corticosteroids — may reduce the mucosal growth-promoting effects
Teduglutide (Gattex) is the gold standard gut repair peptide — FDA-approved with extensive clinical data for short bowel syndrome. The colonoscopy requirement reflects how seriously it drives intestinal cell proliferation. For serious gut conditions, it's unmatched. For general gut health, BPC-157 + KPV is more accessible and sufficient for most users.
Stats
Sources & Studies
Jeppesen PB. et al., Gastroenterology, 2012